NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.809
+0.058 (7.78%)
At close: Apr 28, 2026, 4:00 PM EDT
0.791
-0.018 (-2.23%)
After-hours: Apr 28, 2026, 6:19 PM EDT
NeuroSense Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Strong Buy
Price Target
$8.50
Upside
+950.81%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Apr 8, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 25, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 17, 2026 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +270.87% | Mar 10, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Mar 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Dec 22, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Nov 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Aug 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +1,630.75% | Jul 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +1,630.75% | May 12, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $7.5 | Strong Buy | Initiates | $7.5 | +827.19% | Jul 17, 2023 |
| Maxim Group | Maxim Group | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +765.37% | Jan 7, 2022 |